Antiallodynic effects of propentofylline Elicited by interrupting spinal glial function in a rat model of bone cancer pain

Journal of Neuroscience Research

Volumn 89, Issue 11, 2011, Pages 1877-1886

  Yao, Ming ^a   Chang, Xiang Yang ^b   Chu, Yu Xia ^a   Yang, Jian Ping ^c   Wang, Li Na ^c   Cao, Hao Qiang ^a   Liu, Ming Juan ^a   Xu, Qi Nian ^c  

^a JIAXING UNIVERSITY   (China)

^b Jiaxing Maternity and Child Health Care Hospital   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Cytokines; Glial cells; Pain; Spinal cord

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; PROPENTOFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BONE CANCER; CANCER PAIN; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIA CELL; IMMUNOHISTOCHEMISTRY; MICROGLIA; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD;

ANIMALS; BONE NEOPLASMS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; NEUROGLIA; PAIN; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; XANTHINES;

EID: 80052623299     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22711     Document Type: Article

References (36)

1. Bachynsky J, McCracken P, Lier D, Alloul K, Jacobs P. 2000. Propentofylline treatment for Alzheimer disease and vascular dementia: an economic evaluation based on functional abilities. Alzheimer Dis Assoc Disord 14: 102-111.
2. Chu YX, Zhang Y, Zhang YQ, Zhao ZQ. 2010. Involvement of microglial P2X7 receptors and downstream signaling pathways in long-term potentiation of spinal nociceptive responses. Brain Behav Immun 24: 1176-1189.
3. Frampton M, Harvey RJ, Kirchner V. 2003. Propentofylline for dementia. Cochrane Database Syst Rev 2: CD002853.
4. Geis C, Graulich M, Wissmann A, Hagenacker T, Thomale J, Sommer C, Schafers M. 2010. Evoked pain behavior and spinal glia activation is dependent on tumor necrosis factor receptor 1 and 2 in a mouse model of bone cancer pain. Neuroscience 169: 463-474.
5. Hald A, Nedergaard S, Hansen RR, Ding M, Heegaard AM. 2009. Differential activation of spinal cord glial cells in murine models of neuropathic and cancer pain. Eur J Pain 13: 138-145.
6. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW. 2000. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6: 521-528.
7. Kittner B. 1999. Clinical trials of propentofylline in vascular dementia. European/Canadian propentofylline study group. Alzheimer Dis Assoc Disord 13: S166-171.
8. Kuroda N, Hamachi Y, Aoki N, Wada M, Tanigawa M, Nakashima K. 1999. Simple and rapid high-performance liquid chromatography analysis of propentofylline and its main metabolites in serum using a direct injection technique. Biomed Chromatogr 13: 340-343.
9. Liang LL, Wang ZY, Lü N, Yang JL, Zhang YQ, Zhao ZQ. 2010a. Involvement of nerve injury and activation of peripheral glial cells in tetanic sciatic stimulation-induced persistent pain in rats. J Neurosci Res 88: 2899-2910.
10. Liang LL, Yang JL, Lu N, Gu XY, Zhang YQ, Zhao ZQ. 2010b. Synergetic analgesia of propentofylline and electroacupuncture by interrupting spinal glial function in rats. Neurochem Res 35: 1780-1786.
11. Liu SL, Yang JP, Wang LN, Jiang M, Qiu QC, Ma ZN, Liu L, Li CF, Ren CG, Zhou J, Li W. 2010. Tibia tumor-induced cancer pain involves spinal p38 mitogen-activated protein kinase activation via TLR4-dependent mechanisms. Brain Res 1346: 213-223.
12. Luger NM, Sabino MA, Schwei MJ, Mach DB, Pomonis JD, Keyser CP, Rathbun M, Clohisy DR, Honore P, Yaksh TL, Mantyh PW. 2002. Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain. Pain 99: 397-406.
13. Medhurst SJ, Walker K, Bowes M, Kidd BL, Glatt M, Muller M, Hattenberger M, Vaxelaire J, O'Reilly T, Wotherspoon G, Winter J, Green J, Urban L. 2002. A rat model of bone cancer pain. Pain 96: 129-140.
14. Mercadante S. 1997. Malignant bone pain: pathophysiology and treatment. Pain 69: 1-18.
15. Mercadante S, Arcuri E. 1998. Breakthrough pain in cancer patients: pathophysology and treatment. Cancer Treat Rev 24: 425-432.
16. Mika J, Osikowicz M, Makuch W, Przewlocka B. 2007. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 560: 142-149.
17. Milligan ED, Langer SJ, Sloane EM, He L, Wieseler-Frank J, O'Connor K, Martin D, Forsayeth JR, Maier SF, Johnson K, Chavez RA, Leinwand LA, Watkins LR. 2005. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci 21: 2136-2148.
18. Raghavendra V, Tanga F, Rutkowski MD, DeLeo JA. 2003. Anti-hyperalgesic and morphine-sparing actions of propentofylline following peripheral nerve injury in rats: mechanistic implications of spinal glia and proinflammatory cytokines. Pain 104: 655-664.
19. Raghavendra V, Tanga FY, DeLeo JA. 2004a. Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology 29: 327-334.
20. Raghavendra V, Tanga FY, DeLeo JA. 2004b. Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci 20: 467-473.
21. Ringheim GE. 2000. Glial modulating and neurotrophic properties of propentofylline and its application to Alzheimer's disease and vascular dementia. Ann N Y Acad Sci 903: 529-534.
22. Rothman SM, Guarino BB, Winkelstein BA. 2009. Spinal microglial proliferation is evident in a rat model of painful disc herniation both in the presence of behavioral hypersensitivity and following minocycline treatment sufficient to attenuate allodynia. J Neurosci Res 87: 2709-2717.
23. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, Clohisy DR, Mantyh PW. 1999. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 19: 10886-10897.
24. Shumilla JA, Samuels I, Johnson KW, Forsayeth JR. 2005. Systemic administration of propentofylline does not attenuate morphine tolerance in non-injured rodents. Neurosci Lett 384: 344-348.
25. Si QS, Nakamura Y, Schubert P, Rudolphi K, Kataoka K. 1996. Adenosine and propentofylline inhibit the proliferation of cultured microglial cells. Exp Neurol 137: 345-349.
26. Sweitzer SM, DeLeo JA. 2011. Propentofylline: glial modulation, neuroprotection, and alleviation of chronic pain. Hdbk Exp Pharmacol 200: 235-250.
27. Sweitzer SM, Schubert P, DeLeo JA. 2001. Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. J Pharmacol Exp Ther 297: 1210-1217.
28. Takeda K, Sawamura S, Sekiyama H, Tamai H, Hanaoka K. 2004. Effect of methylprednisolone on neuropathic pain and spinal glial activation in rats. Anesthesiology 100: 1249-1257.
29. Tawfik VL, Lacroix-Fralish ML, Bercury KK, Nutile-McMenemy N, Harris BT, Deleo JA. 2006. Induction of astrocyte differentiation by propentofylline increases glutamate transporter expression in vitro: heterogeneity of the quiescent phenotype. Glia 54: 193-203.
30. Tawfik VL, Nutile-McMenemy N, Lacroix-Fralish ML, Deleo JA. 2007. Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury. Brain Behav Immun 21: 238-246.
31. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. 2007. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun 21: 131-146.
32. Watkins LR, Hutchinson MR, Rice KC, Maier SF. 2009. The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 30: 581-591.
33. Wieseler FJ, Maier SF, Watkins LR. 2004. Glial activation and pathological pain. Neurochem Int 45: 389-395.
34. Yao M, Yang JP, Wang LN, Cheng H, Zhang YB, Xu QN, Wu YW. 2008. Feasibility of establishment of rat model of bone cancer pain by using Walker 256 cells cultured in vitro or in vivo. Zhonghua Yi Xue Za Zhi 88: 880-884.
35. Zhang RX, Liu B, Wang LB, Ren K, Qiao JT, Bermana BM, Lao LX. 2005. Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain 118: 125-136.
36. Zhang YQ, Ji GC, Wu GC, Zhao ZQ. 2002. Excitatory amino acid receptor antagonists and electroacupuncture synergetically inhibit carrageenan-induced behavioral hyperalgesia and spinal fos expression in rats. Pain 99: 525-535.